All Stories

  1. Mechanisms of ibrutinib resistance in chronic lymphocytic leukaemia and non-Hodgkin lymphoma

    Article • British Journal of Haematology, April 2015, Wiley

    Professor Y. Lynn Wang

  2. Functional characterization of BTKC481S mutation that confers ibrutinib resistance: exploration of alternative kinase inhibitors

    Article • Leukemia, September 2014, Springer Science + Business Media

    Professor Y. Lynn Wang

  3. Characterization of ibrutinib-sensitive and -resistant mantle lymphoma cells

    Article • British Journal of Haematology, June 2014, Wiley

    Professor Y. Lynn Wang

  4. Ibrutinib Resistance in Chronic Lymphocytic Leukemia

    Article • New England Journal of Medicine, June 2014, New England Journal of Medicine (NEJM/MMS)

    Professor Y. Lynn Wang

  5. BTK inhibition targets in vivo CLL proliferation through its effects on B-cell receptor signaling activity

    Article • Leukemia, November 2013, Springer Science + Business Media

    Professor Y. Lynn Wang

  6. Laboratory Practice Guidelines for Detecting and Reporting JAK2 and MPL Mutations in Myeloproliferative Neoplasms

    Article • Journal of Molecular Diagnostics, November 2013, Elsevier

    Professor Y. Lynn Wang

  7. Molecular Monitoring of Chronic Myeloid Leukemia

    Article • Journal of Molecular Diagnostics, September 2013, Elsevier

    Professor Y. Lynn Wang

  8. Targeting the Hsp90-associated viral oncoproteome in gammaherpesvirus-associated malignancies

    Article • Blood, August 2013, American Society of Hematology

    Professor Y. Lynn Wang

  9. SYK inhibition and response prediction in diffuse large B-cell lymphoma

    Article • Blood, October 2011, American Society of Hematology

    Professor Y. Lynn Wang

  10. Establishment of the first World Health Organization International Genetic Reference Panel for quantitation of BCR-ABL mRNA

    Article • Blood, August 2010, American Society of Hematology

    Professor Y. Lynn Wang

  11. Activities of SYK and PLC 2 Predict Apoptotic Response of CLL Cells to SRC Tyrosine Kinase Inhibitor Dasatinib

    Article • Clinical Cancer Research, January 2010, American Association for Cancer Research (AACR)

    Professor Y. Lynn Wang

  12. JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms

    Article • Nature Genetics, March 2009, Springer Science + Business Media

    Professor Y. Lynn Wang

  13. Early events of B-cell receptor signaling are not essential for the proliferation and viability of AIDS-related lymphoma

    Article • Leukemia, November 2008, Springer Science + Business Media

    Professor Y. Lynn Wang

  14. Tyrosine kinase inhibition in diffuse large B-cell lymphoma: molecular basis for antitumor activity and drug resistance of dasatinib

    Article • Leukemia, July 2008, Springer Science + Business Media

    Professor Y. Lynn Wang